Life Sciences. GxP-grade evidence for software, AI, and the supply chain underneath.
Pharma, biotech, and clinical research organisations run on validated systems and trial-grade data. 21 CFR Part 11, GAMP 5, ICH E6(R3), and the emerging AI-in-trials guidance turn every CI build and every model deployment into a regulator-visible artefact. Safeguard makes that artefact a signed pipeline output — not a year-long validation exercise.
Four forces converging on every trial submission.
E-signature, data integrity, AI-in-trials, and CRO oversight — all hitting one validated pipeline.
21 CFR Part 11 electronic signatures
FDA expects electronic records and e-signatures with full traceability — who, what, when, why, and the audit trail behind it. Software that touches trial data inherits the same obligation as the records themselves.
Clinical-trial data integrity (ALCOA+)
Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available. Any software in the trial data path has to demonstrably preserve those properties.
EMA / PMDA AI-in-trials guidance
Draft guidance from the EMA and PMDA on AI in clinical research is converging fast. Lineage, validation, drift, and explainability are no longer optional — they have to be in the submission.
Vendor due diligence across CROs
Sponsors run trials through a layered CRO ecosystem. Due diligence cannot stop at the prime contractor; sub-tier vendors carry the same trial data and the same regulator-visible risk.
Capability mapped to inspection-ready expectation.
GxP-validated SBOM pipeline
SBOM emission, signing, retention, and querying run inside a GxP-validated CI pipeline. The pipeline itself ships with IQ / OQ / PQ evidence and a validation summary suitable for inspection.
Clinical-AI model lineage attestation
Every AI model used in the trial workflow carries a signed lineage record — training data scope, training run hash, validation results, deployed version. Available to the regulator as an attestation, not a slide.
Cross-CRO vendor risk
Continuous monitoring across prime CROs and their sub-tier vendors. Concentration risk, residency posture, and breach signals are visible at the sponsor level — not just at quarterly review meetings.
AI-BOM for trial submissions
IND / NDA / MAA submissions increasingly require an AI bill of materials. Safeguard generates the AI-BOM from the same pipeline that emits the software SBOM — one source of truth, machine-readable.
Frameworks the platform is mapped to.
Pre-mapped control narratives and evidence in the formats inspectors at CDER, CBER, EMA, and PMDA already accept.
A typical deployment across sponsor and CRO sites.
GxP-validated CI pipeline, signed trial-AI provenance, multi-site evidence sync, and a CDER / CBER-ready trust packet.
- 01
GxP-validated CI pipeline
CI / CD agents, signing infrastructure, and SBOM emission run inside a validated environment. Change control, IQ / OQ / PQ, and validation summary live with the pipeline.
- 02
Signed trial-AI provenance
Trial AI models — eligibility, adjudication, safety signal — carry signed lineage from training run to deployed version. SHA-pinned weights, signed model cards.
- 03
Multi-site evidence sync
Sponsor sites and CROs across US, EU, and APAC share a common evidence store with per-region residency. Inspection-ready from any site, no email roundtrips.
- 04
CDER / CBER-ready trust packet
Pre-mapped submission packet for FDA CDER / CBER, EMA, and PMDA. SBOM, AI-BOM, VEX, audit trail, and validation summary — exported in the formats the reviewer already accepts.
Four risk surfaces every quality and security lead tracks.
Clinical-trial AI model drift
Eligibility, adjudication, and safety-signal models drift quietly as data distributions move. Drift inside a trial is a data-integrity event, not a software bug — and the inspector will treat it that way.
CRO vendor compromise
Prime CROs and sub-tier vendors hold trial data, eCRF systems, and randomisation services. A breach upstream becomes the sponsor's reportable incident and the sponsor's clock.
IND / NDA submission AI lineage gaps
Submissions that reference AI-assisted analysis need a complete lineage record. A gap in lineage becomes an information request from the reviewer — and a delay to the program.
Lab-equipment firmware vulnerabilities
Sequencers, chromatography systems, and bench instruments run software that nobody patches between calibrations. The connected-lab surface is now part of the GxP perimeter.
What is actually hitting life sciences this year.
Ransomware targeting pharma R&D networks
R&D and trial-operations networks are now coordinated targets. Reachability-aware prioritisation turns thousands of generic CVEs into the short list that actually threatens the program.
Eagle reachability + KEV prioritisationCRO data leakage events
Sub-tier CRO breaches cascade into sponsor inboxes — and into regulator filings. Continuous TPRM with concentration-risk visibility surfaces the exposure before the notification clock starts.
TPRM with concentration risk heatmapAI-trial model poisoning
Adversarial inputs and training-data tampering quietly degrade trial AI. Signed lineage and runtime drift detection make poisoning a visible event, not a missing dataset.
AI-BOM + runtime model integrityVendor SBOM gaps in IND submissions
Inspectors are reading submission SBOMs and asking for the missing components. A signed, complete SBOM pipeline closes those gaps before the submission lands.
Signed SBOM + attestation21 CFR Part 11 e-signature drift
Quiet changes to e-signature flows and audit-trail capture create inspection-finding risk. Continuous control evaluation replaces the annual self-audit.
Compliance evidence pipelineQuantified benefits for life sciences.
Numbers from production deployments inside sponsors and CROs. Same inspector, same trial, dramatically less submission overhead.
Submission-ready evidence, trial-grade integrity.
Talk to the team about GxP-validated SBOM pipelines, AI-BOM for submissions, and a CRO oversight posture that holds up under inspection.
Industries facing a version of this problem
Pharma & Biotech Manufacturing
21 CFR Part 11 and EU Annex 11 across the production estate.
View industryMedical Devices
The FDA premarket SBOM mandate, per submission.
View industryHealthcare
HIPAA and HITECH over systems that cannot be taken offline.
View industryLegal
Client confidentiality SLAs you are contractually held to.
View industryWhat Life Sciences usually rolls out first
Self-healing security runs on Safeguard.
Your first fix PR is minutes away.
No sales call required, even your agent can complete the purchase over MCP.